Tiltan Pharma
 
Medical advisors
Prof Michael Carducci
Michael A. Carducci, MD, is a Professor of Oncology and Urology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore Maryland. He is Co-Leader of the Prostate Cancer / Genitourinary Oncology Program and Co-Leader of the Chemical Therapeutics Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Overall, his laboratory and clinical research focus is on the development and evaluation of new therapies for urologic cancers. Dr. Carducci is a member of the American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO) and American Urological Association (AUA). He is the Chair of the Prostate Cancer Subcommittee of the Genitourinary Oncology Committee of ECOG, serves as an alternate to the GU Steering Committee for the NCI. Dr. Carducci is also a full member of the Investigational Drug Steering Committee for the NCI. Within ASCO, he is currently chair of the Scientific Program Committee and has previously served on the Cancer Education, Scientific Program, and Grants Selection Committees.

Prof Ian Tannock
Prof. Ian Tannock is a Senior Scientist Division of Applied Molecular Oncology Ontario Cancer Institute (OCI). Prof. Tannock has a long-standing interest in improving methods for undertaking clinical trials, and especially in use of endpoints such as quality-of-life that reflect patient benefit directly. We have applied these endpoints in clinical trials for patients with prostate and breast cancer.

Dr Susan Halabi
Dr. Halabi is an associate Professor at the Department of Biostatistics and Bioinformatics at Duke University. She is a member of the external advisory board at Memorial Sloan Kettering Cancer Center. Member of the Central Institutional Review Board, National Cancer Institute
and a member of Cancer Biomarker Study Section at the National Cancer Institute, National Institutes of Health. She is the Author of numerous articles.